Translate Bio Inc., of Lexington, Mass., has filed for an IPO to raise up to $115 million. The company is developing an mRNA therapeutic platform with lead product candidate, MRT-5005, targeting cystic fibrosis, and a phase I/II trial has been initiated. The company plans to list on Nasdaq under the symbol TBIO.